• Publications
  • Influence
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
SummaryBackground: The role of bevacizumab, a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor, in the treatment of pancreatic cancer remains unclear. TheExpand
  • 67
  • 3
The impact of fluid intervention on complications and length of hospital stay after pancreaticoduodenectomy (Whipple’s procedure)
BackgroundThere is limited information on the impact on perioperative fluid intervention on complications and length of hospital stay following pancreaticoduodenectomy. Therefore, we conducted aExpand
  • 42
  • 1
  • PDF
Hepatobiliary and pancreatic: Systemic mastocytosis with portal hypertension
Mastocytosis is a rare disease characterised by the excessive accumulation of mast cells in one or more tissues. The most common form is mastocytosis limited to the skin (cutaneous mastocytosis).Expand
GET BUSY LIVING OR GET BUSY DYING: WAITING FOR THE DEATH PENALTY, A COMPARISON OF THE APPEALS PROCESS IN THE UNITED STATES AND THE PEOPLE’S REPUBLIC OF CHINA
This paper looks at the death penalty in the United States and China with a comparison of the judicial system in each country. The paper examines the speed at which China processes their deathExpand
  • 1
High rate of clinical complete response to weekly outpatient chemotherapy in oral carcinoma patients using a new regimen of cisplatin, 5-fluorouracil, and bleomycin alternating with methotrexate and
A Phase II trial was initiated to evaluate the response to and toxicity of a new regimen of weekly outpatient neoadjuvant chemotherapy in patients with oral carcinoma. Patients with previouslyExpand